{"entity":{"id":"nct06375733","kind":"trial","name":"A Study of GFH009 in Combination With Zanubrutinib in Subjects With Relapsed or Refractory DLBCL","aka":[],"tldr":"A phase 1/2 trial of Zanubrutinib in diffuse large B-cell lymphoma, run by Genfleet Therapeutics (Shanghai) Inc., now recruiting.","summary":"A Study of GFH009 in Combination With Zanubrutinib in Subjects With Relapsed or Refractory DLBCL is a phase 1/2 interventional study registered as NCT06375733 by Genfleet Therapeutics (Shanghai) Inc., with 51 participants planned, started 2024-03-20 and due to reach its primary completion in 2026-12-31. Interventions recorded: GFH009 and Zanubrutinib.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06375733","url":"https://clinicaltrials.gov/study/NCT06375733"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["dlbcl"],"sections":[],"technologies":["kinase-inhibitors"],"targets":[],"drugs":["zanubrutinib"],"companies":["genfleet"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06375733","phase":"1/2","setting":"A Phase Ib/II, Multicenter, Open-label, Single-arm Study to Assess the Safety and Efficacy of GFH009 in Combination With Zanubrutinib in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)","sponsor":"Genfleet Therapeutics (Shanghai) Inc.","participation":[{"nct":"NCT06375733","source":"https://clinicaltrials.gov/study/NCT06375733","fetchedAt":"2026-10-07T16:54:36.402Z","studySha256":"993ee04d5599dbcf6dba56ce9f0ff45a9202ebcfa23000af5e21a369e658bfd7","overallStatus":"RECRUITING","lastUpdatePosted":"2025-08-12","leadSponsor":"Genfleet Therapeutics (Shanghai) Inc.","collaboratorCount":0,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":51,"enrolmentType":"ESTIMATED","siteCount":2,"recruitingSiteCount":2,"countries":["China"]}],"started":"2024-03-20","startedType":"actual","enrolled":51,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06375733/","neighbours":{"cancer":[{"id":"dlbcl","kind":"cancer","name":"Diffuse large B-cell lymphoma","route":"/cancers/dlbcl/"}],"technology":[{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"drug":[{"id":"zanubrutinib","kind":"drug","name":"Zanubrutinib","route":"/drugs/zanubrutinib/"}],"company":[{"id":"genfleet","kind":"company","name":"GenFleet Therapeutics","route":"/companies/genfleet/"}]}}